IHAM
KZR

Integral Health Asset Management’s Kezar Life Sciences KZR Stock Holding History

Integral Health Asset Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,000
Closed -$119K – 81
2021
Q1 		$119K Buy
+2,000
New +$117K 0.03% 69

Other funds holding KZR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Integral Health Asset Management's KZR Position: Q2 2021 in Review

Integral Health Asset Management sold out of Kezar Life Sciences (KZR) in Q2 2021, closing a stake of 2,000 shares — an estimated $119K sold.

Integral Health Asset Management first reported a position in KZR in Q1 2021 and held it in 1 quarter. The position peaked at $119K in Q1 2021. 75 funds tracked by Wall St. Rank hold KZR as of Q2 2021.

  • Integral Health Asset Management reported no remaining Kezar Life Sciences position as of Q2 2021 after selling out during the quarter.
  • Integral Health Asset Management sold 2,000 Kezar Life Sciences shares in Q2 2021, an estimated $119K.
  • Integral Health Asset Management first reported a position in Kezar Life Sciences in Q1 2021 and held it in 1 quarter.
  • Integral Health Asset Management's Kezar Life Sciences position peaked at $119K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2021.

Based on Integral Health Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.